{"id":"NCT01644175","sponsor":"Sanofi","briefTitle":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2014-04","completion":"2014-04","firstPosted":"2012-07-18","resultsPosted":"2015-11-06","lastUpdate":"2015-11-06"},"enrollment":316,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Placebo (for alirocumab)","otherNames":[]},{"type":"DRUG","name":"Alirocumab","otherNames":["SAR236553","REGN727"]},{"type":"DRUG","name":"Lipid-Modifying Therapy (LMT)","otherNames":[]}],"arms":[{"label":"Placebo Q2W","type":"PLACEBO_COMPARATOR"},{"label":"Alirocumab","type":"EXPERIMENTAL"}],"summary":"Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9).\n\nPrimary Objective of the study:\n\n* To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable maximally tolerated daily statin therapy with or without other lipid-modifying therapy (LMT) in comparison with placebo after 24 weeks of treatment in high cardiovascular (CV) risk participants with hypercholesterolemia\n\nSecondary Objectives:\n\n* To evaluate the effect of alirocumab in comparison with placebo on LDL-C at other time points\n* To evaluate the effect of alirocumab on other lipid parameters\n* To evaluate the safety and tolerability of alirocumab","primaryOutcome":{"measure":"Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis","timeFrame":"From Baseline to Week 52","effectByArm":[{"arm":"Placebo Q2W","deltaMin":-2.3,"sd":2.7},{"arm":"Alirocumab 75/150 mg Q2W","deltaMin":-48.2,"sd":1.9}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":6},"locations":{"siteCount":76,"countries":["United States"]},"refs":{"pmids":["25240705","26027630","34298554","30183102","27777279"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":107},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Urinary tract infection","Dizziness","Arthralgia"]}}